Previous 10 | Next 10 |
Socket Mobile (SCKT) +123% on Q3 results.Dogness (DOGZ) +60% after announcing partnership with Hangzhou Huayuan Pet Products and Shanghai Chongai Trading Co. Ltd.Zedge (ZDGE) +47% on Q4 results.Solid Biosciences (SLDB) +28% on announcing collaborat...
Cassava Sciences (SAVA) is an after-hours jumper, up 26.3% postmarket on heavy volume after getting a vote of confidence via a Street-high price target from Cantor Fitzgerald. The firm set its target to $24, implying a healthy 172% upside. It's citing the promise of its first-in-class filamin...
As the pandemic resurges, early vaccine trials are reaching the home stretch. Vaccine results now pushed back to mid-to-late November at the earliest, and there have been delays in therapeutic treatments. Healthcare overall has been burdened by the uncertainty on the Affordable Ca...
Are These The Best Biotech Stocks To Buy Right Now? One of the hottest investment themes in the stock market this year centered around biotech stocks . If you combine the words “biotech” and “small-cap” together, that could be a great recipe for b...
Cassava Sciences (NASDAQ: SAVA) , a clinical-stage biotech, certainly had a month to remember in September. Specifically, the biotech's stock gained an eye-popping 273.7% last month, according to data provided by S&P Global Market Intelligence . Cassava's shares exploded...
Anti-amyloid and anti-tau drugs only slightly slow down the progression of Alzheimer's disease because misfolded amyloid and tau proteins are only two among several factors that can trigger the disease. To treat Alzheimer's disease, it is probably necessary to slow down the production...
AUSTIN, Texas, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biopharmaceutical company focused on Alzheimer’s disease, today announced that clinical results of its Phase 2b study of sumifilam have been selected as a late-breaking oral pres...
In May, Cassava Sciences (NASDAQ: SAVA) stock was down as much as 75% after management revealed that its experimental drug sumifilam did not meet its phase 2 study's primary endpoints for targeting Alzheimer's disease. The drug has been resurrected, however, after its stud...
Cassava Sciences (SAVA) President and CEO Barbier Remi purchases 1,000 shares at average $9.59/share. His beneficial ownership in the company now tallies at 1.08M shares.Following the positive data on lead Alzheimer's drug and news on insider buying, the stock has gained about 212% ...
Are These On Your List Of Best Biotech Stocks To Buy Now? Biotech stocks have been the true performer for the year 2020. Amid the ongoing pandemic, top biotech stocks have taken the center stage. Those with COVID-19 programs under development have been reaching new highs. Just y...
News, Short Squeeze, Breakout and More Instantly...
Cassava Sciences Inc. Company Name:
SAVA Stock Symbol:
NYSE Market:
$126.3 Million In Total Gross Proceeds from Warrant Distribution. Over 1,900 Patients with Alzheimer’s Disease Are Randomized in Phase 3 Trials of Simufilam. Over 735 Patients Have Completed a Phase 3 Trial of Simufilam. AUSTIN, Texas, May 10, 2024 (GLOBE NE...
2024-05-08 16:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company”), a biotechnology company focused on Alzheimer’s disease, today announced total gross proceeds of over $125 million from cash-exercises of warrants that were previously distri...